Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 24;330(6012):1774.
doi: 10.1126/science.1197623. Epub 2010 Dec 9.

Decreased clearance of CNS beta-amyloid in Alzheimer's disease

Kwasi G Mawuenyega  1 , Wendy Sigurdson, Vitaliy Ovod, Ling Munsell, Tom Kasten, John C Morris, Kevin E Yarasheski, Randall J Bateman
Affiliations

Decreased clearance of CNS beta-amyloid in Alzheimer's disease

Kwasi G Mawuenyega et al. Science. .

Abstract

Alzheimer's disease is hypothesized to be caused by an imbalance between β-amyloid (Aβ) production and clearance that leads to Aβ accumulation in the central nervous system (CNS). Aβ production and clearance are key targets in the development of disease-modifying therapeutic agents for Alzheimer's disease. However, there has not been direct evidence of altered Aβ production or clearance in Alzheimer's disease. By using metabolic labeling, we measured Aβ42 and Aβ40 production and clearance rates in the CNS of participants with Alzheimer's disease and cognitively normal controls. Clearance rates for both Aβ42 and Aβ40 were impaired in Alzheimer's disease compared with controls. On average, there were no differences in Aβ40 or Aβ42 production rates. Thus, the common late-onset form of Alzheimer's disease is characterized by an overall impairment in Aβ clearance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Aβ kinetics in the CNS of twelve AD participants (red triangles) and twelve controls (blue circles). The amount of labeled Aβ42 and Aβ40 was measured and compared between groups to measure production and clearance rates of both Aβ species. (A) The average normalized labeled Aβ42 time course. (B) Aβ42 clearance rate during the clearance phase (hours 24–36). (C) Normalized labeled Aβ40 time course. (D) Aβ40 clearance in AD compared to controls. (E) The average fractional synthesis rates of Aβ42 and Aβ40 in AD participants and cognitively normal controls. (F) The average fractional clearance rates of Aβ42 and Aβ40.
See this image and copyright information in PMC

Comment in

  • It is all about clearance.
    Mattsson N, Olsson B, Andreasson U, Portelius E, Zetterberg H. Mattsson N, et al. Biomark Med. 2011 Apr;5(2):202. Biomark Med. 2011. PMID: 21614802 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hardy J, Selkoe DJ. Science. 2002 Jul 19;297:353. - PubMed
    1. Cummings JL. N Engl J Med. 2004 Jul 1;351:56. - PubMed
    1. Scheuner D, et al. Nat Med. 1996 Aug;2:864. - PubMed
    1. Bateman RJ, et al. Nat Med. 2006 Jul;12:856. - PMC - PubMed
    1. Bateman RJ, et al. Annals of Neurology. 2009;66:48. - PMC - PubMed

Publication types